Select Language

SOST

SOST Overview

English Name	Sclerostin	Approved Drugs	1
Drugs in Clinical Trials	6	Target Synonym	Sclerostin，UNQ2976/PRO7455/PRO7476，SOST，Sclerosteosis，DAND6，SOST1，VBCH，CDD
Highest Development Stage	Approved

English Name	Sclerostin
Target Synonym	Sclerostin，UNQ2976/PRO7455/PRO7476，SOST，Sclerosteosis，DAND6，SOST1，VBCH，CDD
Approved Drugs	1
Drugs in Clinical Trials	6
Highest Development Stage	Approved

SOST Product List

Product Category
Protein (2)
Product Status
Launched (2)
Species
Human (2)
Tag
His Tag (2)
Conjugate
Unconjugated (1)Biotin-labeled (1)

Cat. No.	Species	Host	Product Description	Structure	Purity	Feature
HST-H5245	Human	HEK293	Human SOST / Sclerostin Protein, His Tag, low endotoxin (HPLC verified)
SOT-H8245	Human	HEK293	Biotinylated Human SOST / Sclerostin Protein, His Tag, ultra sensitivity (primary amine labeling)

Total: 2

SOST Background

Sclerostin is a secreted glycoprotein with a C-terminal cysteine knot-like (CTCK) domain and sequence similarity to the DAN (differential screening-selected gene aberrative in neuroblastoma) family of bone morphogenetic protein (BMP) antagonists. Loss-of-function mutations in this gene are associated with an autosomal-recessive disorder, sclerosteosis, which causes progressive bone overgrowth. A deletion downstream of this gene, which causes reduced sclerostin expression, is associated with a milder form of the disorder called van Buchem disease. [provided by RefSeq, Jul 2008]

SOST Synonyms

SOST,VBCH

Clinical Drug Information

English Name	Research Code	Highest Development Stage	Company	Indication	Clinical Trial
Setrusumab	UX143; NOV-3; MOR-05813; BPS-804	Phase 3 Clinical	Morphosys Ag, Novartis Pharma Ag	Bone Diseases, Metabolic; Hypophosphatasia; Osteogenesis Imperfecta; Osteoporosis; Renal Insufficiency, Chronic	Details
AGA-2115	AGA2115; AGA-2115	Phase 2 Clinical	Angitia Biopharmaceuticals (Guangzhou) Ltd	Osteogenesis Imperfecta	Details
AGA-2118	AGA-2118	Phase 2 Clinical	Angitia Biomedicines Ltd	Osteoporosis; Osteoporosis, Postmenopausal	Details
Resugosbart	SHR-1222	Phase 1 Clinical	Jiangsu Hengrui Medicine Co Ltd, Shanghai Hengrui Pharmaceutical Co Ltd, Suzhou Suncadia Biopharmaceuticals Co Ltd	Osteoporosis; Osteoporosis, Postmenopausal	Details
Romosozumab biosimilar(Zhuhai Federation Biomedicine)		Phase 1 Clinical	Zhuhai Federation Biomedicine Co Ltd	Osteoporosis, Postmenopausal	Details
Blosozumab	TST002; LY-2541546; TST002-IgG4	Phase 1 Clinical	Eli Lilly And Company	Osteoporosis; Osteoporosis, Postmenopausal	Details

Marketed Drug Information

English Name	Research Code	Highest Development Stage	Company	Earliest Brand Name	Earliest Approval Country	Earliest Indication	Earliest Approval Company	Earliest Approval Date	Indication	Clinical Trial
Romosozumab	CDP-7851; AMG-785	Approved		Evenity, EVENITY	Japan	Osteoporosis	Amgen Inc	2019-01-08	Bone Diseases, Metabolic; Fractures, Bone; Osteogenesis Imperfecta; Osteoporosis; Osteoporosis, Postmenopausal	Details